An Open Label Study to Determine the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia A.

Condition:   Hemophilia A Intervention:   Drug: Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection Sponsors:   Zhengzhou Gensciences Inc;   Haimen Gensciences lnc Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials